A fluidic device for detecting a target molecule in a fluid sample comprising a blocking chamber in fluidic communication with a detection chamber forming a blocking-detection chamber pair, the blocking chamber provided with at least one reagent for binding a non-target molecule in the sample, the blocking chamber adapted to maintain at least a portion of the bound non-target molecule within the blocking chamber, the detection chamber comprising at least one reagent for binding a target-molecule such that the target-molecule may be detected. The device comprises a combination detection chamber adapted to receive at least one reagent for binding both target and non-target molecules such that the combination of target and non-target molecules may be detected by binding to a detector.

The present invention relates to an improved assay and in particular to an improved assay that is capable of consistently measuring antibody titre, especially neutralising antibody (NAb) titre, at lower thresholds and/or with greater speed than conventionally-known assays. The invention further relates to use of such assays in combination with the provision of gene therapy and/or in combination with the provision of methods aimed at removal/depletion of neutralising antibodies from a patient.

The present invention is directed towards methods, compositions and kits for testing SARS-CO-V2 virus in a sample. The methods determine the presence of a viral 3CL protease by contacting the sample with a peptide compound capable of being cleaved by the protease to form peptide compound fragments. Detection of a peptide compound fragment confirms the presence of the virus.

A sample capture and testing system can include a primary receptacle for receiving a fluid sample, where the primary receptacle has a sensor for label-free detection of an analyte disposed at one side. The primary receptacle can be incorporated in a needle for in vivo capture and testing of a sample. The primary receptacle can be incorporated into a specimen container and used as part of a point of care device.

Certain aspects of the present disclosure generally relate to systems and methods for determining viruses. For instance, some aspects are directed to systems and methods for determining viruses using a partitioning system. Within the partitioning system, the virus may partition into one or more phases. In some cases, a virus-binding moiety facilitates partitioning of the virus. The phases may be assayed to determine the virus based on, e.g., quantitative or qualitative assessments of the distribution of virus-binding and/or signaling moieties. The virus-binding moiety may be attached to particles that may form a complex around a virus. The complex may be detectable without a signaling moiety (e.g., as a color change) in some embodiments. In some cases, more than one virus may be determined. For example, a virus-binding moiety may substantially alter the partitioning behavior of one virus or complex, relative to another, by being selective for the first virus.

The present invention encompasses a diagnostic test and method to authenticate the veracity of a vaccine. The diagnostic test and method are especially useful in a specific and sensitive immunochromatographic (“ICT”) assay, performable within about 15 minutes, for the authentication, validation, and veracity of a vaccine in a vial prior to administration to a human, such as a COVID-19 vaccine.

The invention concerns methods for early detection, monitoring and prognosis of a flavivirus-induced infection, comprising the detection of a complex formed by the flavivirus non-structural glycoprotein NS1 and plasma lipoprotein particles in a biological anti-NS1 Mab sample during the clinical phase of the infection.

The disclosure relates to test kits and methods for detecting the presence of multiple human papilloma vims polynucleotides in a biological sample.

Provided are novel human-derived antibodies specifically recognizing polyomavirus polypeptides, preferably capable of binding to polyomaviruses of the type of JC virus (JCV) and/or BK virus (BKV) as well as methods related thereto. Furthermore, assays and kits related to antibodies specific for polyomaviruses, polyomavirus VP1 and or polyomavirus VP1 Virus-Like Particles (VLPs), preferably of the type of JCV and/or BKV, are disclosed. The human-derived antibodies as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for polyomavirus targeted immunotherapy and diagnostics.

Arrays comprising probes comprising peptides from more than one flavivirus are provided. Methods of using the arrays, as well as kits and systems comprising the arrays are also provided.